Human mesenchymal stromal cell proteomics: Contribution for identification of new markers and targets for medicine intervention

Expert Review of Proteomics

Volumn 9, Issue 2, 2012, Pages 217-230

  Faça, Vitor Marcel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cell surface markers; mesenchymal stromal stem cells; proteomics; secretome

Indexed keywords

COMPLEMENT COMPONENT C1S; CONNECTIVE TISSUE GROWTH FACTOR; ENOLASE; FIBRONECTIN; FOLLISTATIN RELATED PROTEIN; GALECTIN 3; GELATINASE A; GLUTATHIONE TRANSFERASE A1; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LEUKEMIA INHIBITORY FACTOR; LUMICAN; MACROPHAGE MIGRATION INHIBITION FACTOR; OSTEOPROTEGERIN; PENTRAXIN 3; PEROXIREDOXIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOLLAGEN C PROTEINASE; PROTEIN TYROSINE PHOSPHATASE; SERINE PROTEINASE INHIBITOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; THIOL OXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG;

ADIPOCYTE; ANGIOGENESIS; APOPTOSIS; CARTILAGE CELL; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL SURFACE; CELL THERAPY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; MASS SPECTROMETRY; MESENCHYMAL STROMA CELL; MITOSIS; OSTEOCYTE; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEOMICS; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; HUMANS; MEMBRANE PROTEINS; MESENCHYMAL STROMAL CELLS; PROTEOME; PROTEOMICS; REGENERATION; REGENERATIVE MEDICINE;

EID: 84859402229     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.12.9     Document Type: Review

References (74)

1. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276(5309), 71-74 (1997).
2. Caplan AI. Mesenchymal stem cells. J. Orthop. Res. 9(5), 641-650 (1991).
3. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999). A seminal study that characterized the differentiation potential of mesenchymal stem or stromal cells (MSCs).
4. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418(6893), 41-49 (2002).
5. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119(11), 2204-2213 (2006).
6. Zuk PA, Zhu M, Ashjian P et al. Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 13(12), 4279-4295 (2002).
7. De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 44(8), 1928-1942 (2001).
8. De Bari C, Dell'Accio F, Vanlauwe J et al. Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheum. 54(4), 1209-1221 (2006).
9. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4), 315-317 (2006).
10. Li X, Ling W, Pennisi A et al. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells 29(2), 263-273 (2011).
11. Choi YH, Kurtz A, Stamm C. Mesenchymal stem cells for cardiac cell therapy. Hum. Gene Ther. 22(1), 3-17 (2011).
12. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol. 10(7), 649-656 (2011).
13. Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M. Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells 29(1), 5-10 (2011).
14. Ciavarella S, Dominici M, Dammacco F, Silvestris F. Mesenchymal stem cells: a new promise in anticancer therapy. Stem Cells Dev. 20(1), 1-10 (2011).
15. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a Phase 2 study. Lancet 371(9624), 1579-1586 (2008).
16. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J. Cell Biochem. 98(5), 1076-1084 (2006).
17. Panepucci RA, Siufi JL, Silva WA et al. Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. Stem Cells 22(7), 1263-1278 (2004). The precursor study that showed the similarities and fine differences among MSCs from different sources.
18. Covas DT, Panepucci RA, Fontes AM et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp. Hematol. 36(5), 642-654 (2008).
19. Unwin RD, Whetton AD. Systematic proteome and transcriptome analysis of stem cell populations. Cell Cycle 5(15), 1587-1591 (2006).
20. Wang D, Park JS, Chu JS et al. Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor β1 stimulation. J. Biol. Chem. 279(42), 43725-43734 (2004). The first proteomic profile of MSCs.
21. Feldmann RE, Bieback K, Maurer MH et al. Stem cell proteomes: a profile of human mesenchymal stem cells derived from umbilical cord blood. Electrophoresis 26(14), 2749-2758 (2005).
22. Wagner W, Feldmann RE, Seckinger A et al. The heterogeneity of human mesenchymal stem cell preparations - evidence from simultaneous analysis of proteomes and transcriptomes. Exp. Hematol. 34(4), 536-548 (2006).
23. Seshi B. Proteomics strategy based on liquid-phase IEF and 2-D DIGE: application to bone marrow mesenchymal progenitor cells. Proteomics 7(12), 1984-1999 (2007).
24. Mareddy S, Broadbent J, Crawford R, Xiao Y. Proteomic profiling of distinct clonal populations of bone marrow mesenchymal stem cells. J. Cell Biochem. 106(5), 776-786 (2009).
25. Seshi B. An integrated approach to mapping the proteome of the human bone marrow stromal cell. Proteomics 6(19), 5169-5182 (2006).
26. Petrak J, Ivanek R, Toman O et al. Déjà vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 8(9), 1744-1749 (2008).
27. Nilsson T, Mann M, Aebersold R, Yates JR, Bairoch A, Bergeron JJ. Mass spectrometry in high-throughput proteomics: ready for the big time. Nat. Methods 7(9), 681-685 (2010).
28. Faca V, Pitteri SJ, Newcomb L et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J. Proteome Res. 6(9), 3558-3565 (2007).
29. Tang J, Gao M, Deng C, Zhang X. Recent development of multi-dimensional chromatography strategies in proteome research. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 866(1-2), 123-132 (2008).
30. Faça VM, Ventura AP, Fitzgibbon MP et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 3(6), e2425 (2008).
31. Meirelles LAS, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 20(5-6), 419-427 (2009).
32. Liu CH, Hwang SM. Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 32(6), 270-279 (2005).
33. Chiellini C, Cochet O, Negroni L et al. Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. BMC Mol. Biol. 9, 26 (2008).
34. Choi YA, Lim J, Kim KM et al. Secretome analysis of human BMSCs and identification of SMOC1 as an important ECM protein in osteoblast differentiation. J. Proteome Res. 9(6), 2946-2956 (2010).
35. Lee MJ, Kim J, Kim MY et al. Proteomic analysis of tumor necrosis factor-a-induced secretome of human adipose tissue-derived mesenchymal stem cells. J. Proteome Res. 9(4), 1754-1762 (2010).
36. Mannello F. Multipotent mesenchymal stromal cell recruitment, migration, and differentiation: what have matrix metalloproteinases got to do with it? Stem Cells 24(8), 1904-1907 (2006).
37. Mannello F, Tonti GA, Bagnara GP, Papa S. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells 24(3), 475-481 (2006).
38. Faça VM, Hanash SM. In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res. 69(3), 728-730 (2009).
39. Niehage C, Steenblock C, Pursche T, Bornhäuser M, Corbeil D, Hoflack B. The cell surface proteome of human mesenchymal stromal cells. PLoS One 6(5), e20399 (2011). This study represents the most detailed cell surface profile of MSCs to date.
40. Lee SK, Kim Y, Kim SS et al. Differential expression of cell surface proteins in human bone marrow mesenchymal stem cells cultured with or without basic fibroblast growth factor containing medium. Proteomics 9(18), 4389-4405 (2009).
41. Foster LJ, Zeemann PA, Li C, Mann M, Jensen ON, Kassem M. Differential expression profiling of membrane proteins by quantitative proteomics in a human mesenchymal stem cell line undergoing osteoblast differentiation. Stem Cells 23(9), 1367-1377 (2005).
42. Jeong JA, Ko KM, Park HS et al. Membrane proteomic analysis of human mesenchymal stromal cells during adipogenesis. Proteomics 7(22), 4181-4191 (2007).
43. Bosch J, Houben AP, Radke TF et al. Distinct differentiation potential of 'MSC' derived from cord blood and umbilical cord: are cord-derived cells true mesenchymal stromal cells? Stem Cells Dev. doi:10.1089/scd.2011.0414 (2012) (Epub ahead of print).
44. Raicevic G, Najar M, Stamatopoulos B et al. The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol. 270(2), 207-216 (2011).
45. Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 308(5727), 1472-1477 (2005). This study not only demonstrated the fine regulation of signaling pathways during MSC differentiation, but also represented a breakthrough in phosphoproteome profiling.
46. Salasznyk RM, Westcott AM, Klees RF et al. Comparing the protein expression profiles of human mesenchymal stem cells and human osteoblasts using gene ontologies. Stem Cells Dev. 14(4), 354-366 (2005).
47. Kim JS, Lee HK, Kim MR, Kim PK, Kim CW. Differentially expressed proteins of mesenchymal stem cells derived from human cord blood (hUCB) during osteogenic differentiation. Biosci. Biotechnol. Biochem. 72(9), 2309-2317 (2008).
48. Sun HJ, Bahk YY, Choi YR, Shim JH, Han SH, Lee JW. A proteomic analysis during serial subculture and osteogenic differentiation of human mesenchymal stem cell. J. Orthop. Res. 24(11), 2059-2071 (2006).
49. Zhang AX, Yu WH, Ma BF et al. Proteomic identification of differently expressed proteins responsible for osteoblast differentiation from human mesenchymal stem cells. Mol. Cell Biochem. 304(1-2), 167-179 (2007).
50. Giusta MS, Andrade H, Santos AV et al. Proteomic analysis of human mesenchymal stromal cells derived from adipose tissue undergoing osteoblast differentiation. Cytotherapy 12(4), 478-490 (2010).
51. Augello A, De Bari C. The regulation of differentiation in mesenchymal stem cells. Hum. Gene Ther. 21(10), 1226-1238 (2010).
52. Lee HK, Lee BH, Park SA, Kim CW. The proteomic analysis of an adipocyte differentiated from human mesenchymal stem cells using two-dimensional gel electrophoresis. Proteomics 6(4), 1223-1229 (2006).
53. Choi CB, Cho YK, Prakash KV et al. Analysis of neuron-like differentiation of human bone marrow mesenchymal stem cells. Biochem. Biophys. Res. Commun. 350(1), 138-146 (2006).
54. Jung H, Kim WK, Kim DH et al. Involvement of PTP-RQ in differentiation during adipogenesis of human mesenchymal stem cells. Biochem. Biophys. Res. Commun. 383(2), 252-257 (2009).
55. Kim WK, Jung H, Kim DH et al. Regulation of adipogenic differentiation by LAR tyrosine phosphatase in human mesenchymal stem cells and 3T3-L1 preadipocytes. J. Cell Sci. 122(22), 4160-4167 (2009).
56. Ji YH, Ji JL, Sun FY et al. Quantitative proteomics analysis of chondrogenic differentiation of C3H10T1/2 mesenchymal stem cells by iTRAQ labeling coupled with on-line two-dimensional LC/MS/MS. Mol. Cell Proteomics 9(3), 550-564 (2010).
57. Li G, Zhang XA, Wang H et al. Comparative proteomic analysis of mesenchymal stem cells derived from human bone marrow, umbilical cord, and placenta: implication in the migration. Proteomics 9(1), 20-30 (2009).
58. Roche S, Delorme B, Oostendorp RA et al. Comparative proteomic analysis of human mesenchymal and embryonic stem cells: towards the definition of a mesenchymal stem cell proteomic signature. Proteomics 9(2), 223-232 (2009).
59. Roche S, Provansal M, Tiers L, Jorgensen C, Lehmann S. Proteomics of primary mesenchymal stem cells. Regen. Med. 1(4), 511-517 (2006).
60. Noël D, Caton D, Roche S et al. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp. Cell Res. 314(7), 1575-1584 (2008).
61. Copland IB, Lord-Dufour S, Cuerquis J et al. Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition. Stem Cells 27(2), 467-477 (2009).
62. Liu L, Yu Q, Lin J et al. Hypoxia-inducible factor-1α is essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood. Stem Cells Dev. 20(11), 1961-1971 (2011).
63. Kadri T, Lataillade JJ, Doucet C et al. Proteomic study of galectin-1 expression in human mesenchymal stem cells. Stem Cells Dev. 14(2), 204-212 (2005).
64. Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 116(19), 3770-3779 (2010).
65. Horwitz EM, Prather WR. Cytokines as the major mechanism of mesenchymal stem cell clinical activity: expanding the spectrum of cell therapy. Isr. Med. Assoc. J. 11(4), 209-211 (2009).
66. Nemeth K, Keane-Myers A, Brown JM et al. Bone marrow stromal cells use TGF-β to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc. Natl Acad. Sci. USA 107(12), 5652-5657 (2010).
67. Nasef A, Chapel A, Mazurier C et al. Identification of IL-10 and TGF-β transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expression 13(4-5), 217-226 (2007).
68. Najar M, Rouas R, Raicevic G et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11(5), 570-583 (2009).
69. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7(2), 131-142 (2006).
70. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119(6), 1420-1428 (2009).
71. Pevsner-Fischer M, Levin S, Zipori D. The origins of mesenchymal stromal cell heterogeneity. Stem Cell Rev. 7(3), 560-568 (2011).
72. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 452(7187), 571-579 (2008).
73. Kyoto Encyclopedia of Genes and Genomes Pathway Database.www.genome.jp/ kegg/pathway.html
74. The Gene Ontology Website.www.geneontology.org